Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Talanta ; 221: 121494, 2021 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-33076099

RESUMO

Ammonium acetate is employed in order to develop a novel HPLC-ICP-MS arsenic speciation methodology applicable to six arsenic species, i.e, AC, AB, AsIII, AsV, DMA and MMA. The most predominant species in the toxicological field are covered in a 30-min chromatogram with reproducible and repeatability peak area ratio. Moreover, typical problems from traditional methods are sorted out by using a robust, high-selective and 75ArCl+ interference-free methodology. Chromatographic and detector optimization ensures low LOQs for each species with acceptable precision and accuracy values obtained using four urinary arsenic speciation PTS enabling to be useful for sub ng mL-1 arsenic exposure assessments.


Assuntos
Arsênio , Arsenicais , Acetatos , Cromatografia Líquida de Alta Pressão , Espectrometria de Massas
2.
Int J Clin Pract ; 69(5): 550-9, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25707623

RESUMO

BACKGROUND: The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain. AIMS: To assess the effect of bB on the prognosis of HF patients with new-onset DM treated with a contemporary medical regime. METHODS: Prospective study of 5314 HF patients with previously unknown DM. Mean age was 71.8±7.9 years, 53.0% were women, and 50.2% had HF with preserved ejection fraction (HFpEF). During a median follow-up of 56.9±18.2 months, 68.9% of the patients died, 88.6% were hospitalised for HF, and 1519 (27.3%) developed DM (62.3% of them received bB, 947 patients). We propensity-matched 572 HF patients with DM on bB, with 572 HF patients with DM non-treated with bB. RESULTS: Beta-blocker therapy was associated with a decreased hazard risk (HR) of all-cause death [HR: 0.68, CI 95% (0.61-0.75)], mainly because of a reduced risk of death from cardiovascular causes [HR: 0.70 (0.64-0.77)] (p<0.001). Similarly, bB was associated with a decreased HR of hospitalisation [HR: 0.82 (0.72-0.92)] (p<0.001). Nevertheless, the 30-day re-admission rate and the number of visits were not significantly associated with bB. These relationships of bB with prognosis were maintained, independently of the gender, the type of HF (HFpEF ot HFdEF), the comorbidities and the medication used (p<0.01). CONCLUSION: Therapy with bB, bisoprolol or carvedilol, is associated with a reduced mortality and morbidity of HF patients with new-onset DM, not only in men but also in women, as well as in patients with HFpEF or HFdEF.


Assuntos
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico , Bisoprolol/uso terapêutico , Carbazóis/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Insuficiência Cardíaca/tratamento farmacológico , Propanolaminas/uso terapêutico , Idoso , Carvedilol , Estudos de Casos e Controles , Feminino , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/mortalidade , Humanos , Masculino , Prognóstico , Estudos Prospectivos , Índice de Gravidade de Doença , Espanha
3.
Int J Clin Pract ; 69(2): 169-79, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25040352

RESUMO

BACKGROUND: The relationship between the fluctuations of the anthropometric indices (AIs) and the prognosis of patients with incident heart failure (HF) in a population-based cohort is unknown. AIMS: To assess the relationship between the fluctuations of the AIs, body mass index (BMI), waist hip ratio (WHR), and weight height ratio (WHeR) and the prognosis of patients with incident HF. METHODS: Anthropometric indices were prospectively measured in a 10-year population-based study of 6492 patients with incident HF (GAMIC cohort). 4530 patients (66.7%) died, during a mean follow-up of 72.7 ± 14.2 months. A time-updated analysis of the changes of the AIs was performed to assess their association with mortality and morbidity (hospitalisations and visits). RESULTS: Patients with incident HF presenting ≥ 5% decrease or ≥ 7% increase of the AIs have an increased mortality [HR ≥ 1.65 (1.52-2.34) or HR ≥ 1.71 (1.58-1.85), respectively, p < 0.001]. Mortality risk increased ≥ 1.43-fold (p = -0.0003) for each 10% change in the AIs. There was an accelerated pattern of reduction in the AIs in the 6 months prior to death, and an accelerated increase in the AIs in the 3 months prior to hospitalisation. These observations were independent of the aetiology (ischaemic vs. non-ischaemic), the type of HF (systolic vs. non-systolic), and other predictors of mortality. CONCLUSIONS: Time-updated changes (increase or decrease) of the AIs, BMI, WHR and weight height ratio are independently associated with the mortality of patients with incident HF.


Assuntos
Antropometria , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/mortalidade , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Estudos de Coortes , Feminino , Insuficiência Cardíaca/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Fatores de Risco , Espanha/epidemiologia , Relação Cintura-Quadril/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...